Phenytoin-oxacillin interactions in normal and uremic sera

Pharmacotherapy

Volumn 17, Issue 2, 1997, Pages 375-378

  Dasgupta, Amitava ^a,d   Sperelakis, Antoinette ^b   Mason, Albert ^a   Dean, Roger ^c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; OXACILLIN; PHENYTOIN; SALICYLIC ACID; VALPROIC ACID;

ANTIBIOTIC THERAPY; ARTICLE; BINDING KINETICS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOALBUMINEMIA; UREMIA;

ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; OXACILLIN; PENICILLINS; PHENYTOIN; PROTEIN BINDING; SERUM ALBUMIN; UREMIA;

EID: 0030953979     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bruni J. Phenytoin. In: Taylor WJ, Diers Caviness MH, eds. A textbook for the clinical application of therapeutic drug monitoring. Irvine, TX: Abbott Laboratories, 1986:253-67.
2. Perucca D, Hebdige S, Frigo G, Lecchini S, Crema A. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther 1980;28:779-89.
3. Monk A, Richens A. Effect of single dose of sodium valproate on serum phenytoin levels and protein binding in epileptic patients. Clin Pharmacol Ther 1980;27:89-95.
4. Fraser DG, Ludden TM, Evans RP, Sutherland EW. Displacement of phenytoin from plasma binding sites by salicylate. Clin Pharmacol Ther 1980;27:165-9.
5. Leonard RF, Rankin GO, Robinson DS, Melnic DE. Phenytoin salicylate interaction. Clin Pharmacol Ther 1981;29:56-60.
6. Dasgupta A. Valproic acid: an update. Check sample. Chicago: American Society for Clinical Pathologists, 1995:101-12.
7. Gugler R, Azornoff DL. Drug protein binding and nephrotic syndrome. Clin Pharmacokinet 1976;1:25-35.
8. Belpaire FM, Bogaert MG, Musche MN. Influence of renal failure on the protein binding of drugs in animals and man. Eur J Clin Pharmacol 1977;11:27-32.
9. McNamara PJ, Lalka D, Gibaldi M. Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 1981;98:730-40.
10. Reidenberg MM, Drayer DE. Alteration of drug protein binding in renal disease. Clin Pharmacokinet 1984;9(suppl): 18-26.
11. Brodie MJ, Muir SE, Agnew E. Protein binding and CSF penetration of phenytoin following acute oral dosing in man. Br J Clin Pharmacol 1985;19:161-8.
12. Dasgupta A, Abu-Alfa A. Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis: role of uremic compounds. Am J Clin Pathol 1992;98:19-25.
13. Dasgupta A, Dennen DA, Dean R, McLawhon R. Displacement of phenytoin from serum carriers by antibiotics: studies with ceftriaxone, nafcillin and sulfamethoxazole. Clin Chem 1991;37:98-101.
14. McEvoy GK, Lilvak K, Welsh OH Jr, eds. AHFS 96 drug information. Bethesda: American Society of Health-System Pharmacists, 1996:288-91.
15. Dromgoole SH. The binding capacity of albumin and renal disease. J Pharmacol Exp Ther 1974;191:318-23.